HK Stock Market Move | LAEKNA-B(02105) increased by over 6%, announcing excellent clinical data for the treatment of HR+/HER2- breast cancer stage Ib with LAE002.

LAEKNA-B (02105) rose more than 6%, reaching a 6.7% increase at the time of publication, trading at 4.78 Hong Kong dollars with a turnover of 5.1623 million Hong Kong dollars. On the news front, at the 2024 European Society for Medical Oncology (ESMO) Congress, Lekai Medicine announced the final data of its innovative product LAE002 combined with fulvestrant (referred to as "combination therapy"), for the treatment of locally advanced or metastatic HR+/HER2- breast cancer patients who have failed standard therapy. In the phase Ib study, the median progression-free survival (PFS) in 18 patients with PIK3CA/AKT1/PTEN mutations was 7.3 months. It is reported that Lekai Medicine initiated the phase III pivotal clinical trial AFFIRM-205 in China in May 2024, led by Academician Xu Binghe of the Cancer Hospital of the Chinese Academy of Medical Sciences, for the treatment of HR+/HER2- breast cancer patients with PIK3CA/AKT1/PTEN alterations. The project is progressing smoothly and ahead of schedule.